A 61-year-old woman with biochemically proven endogenous hyperinsulinemic hypoglycemia and negative conventional imaging underwent 68 Ga-NOTA-exendin-4 PET/CT for localization of insulinoma. Focal intense radioactivity in the tail of the pancreas was observed that was subsequently confirmed as insulinoma pathologically after surgical resection. In addition, esophageal carcinoma with lymph node and hepatic metastases was found by FDG PET/CT in the same patient. Neither the primary carcinoma nor the metastases showed increased radioactivity on 68 Ga-NOTAexendin-4 PET/CT.
. A 61-year-old woman presented symptoms of neuroglycopenia for 11 years. Whipple's triad (recorded lowest serum glucose level of 0.8 mmol/L) with inappropriately high serum insulin and C-peptide level was repeatedly documented during the course of disease. Insulinoma was considered as the most common etiology of endogenous hyperinsulinemic hypoglycemia in this patient without a known history of diabetes. However, contrast-enhanced CT, MRI, endoscopic ultrasound, arteriography of superior mesenteric artery, and somatostatin receptor scintigraphy showed no evidence of insulinoma. She was then referred for 68 Ga-NOTA-exendin-4 PET/CT for localization of insulinoma, which was approved by the institutional review board of our hospital, and written informed consent was obtained from the patient. 68 Ga-NOTA-exendin-4 is a novel PET tracer targeting glucagon-like peptide 1 receptor (GLP-1R), which is highly overexpressed on benign insulinoma cell surface in very high incidence and extremely high density. 1,2 GLP-1R imaging with exendin-4 based tracer was recently reported to be very sensitive for localization of insulinomas. [3] [4] [5] [6] [7] [8] PET/CT images were acquired 50 minutes after IV injection of 51.8 MBq of 68 Ga-NOTA-exendin-4. On MIP image of the PET (A), a focal lesion with intense radioactivity in the left upper abdomen (arrow) was clearly seen. Both kidneys and bladder showed physiological uptake. On axial images (B, PET; C, fusion), this intense radioactivity corresponded to a lesion in the tail of the pancreas (arrow), with the average and SUV max of 20.0 and 52.9, respectively. The 68 Ga-exendin-4 PET/CT finding was interpreted as insulinoma in the tail of the pancreas. This tumor was isoenhanced on arterial phase of contrast-enhanced CT image (D). T1-weighted MRI (E) showed the tumor had similar signal intensity compared with normal pancreas.
